Cytomegalovirus-mediated activation of pyrimidine biosynthesis drives UDP–sugar synthesis to support viral protein glycosylation

Abstract

Human cytomegalovirus (HCMV) induces numerous changes to the host metabolic network that are critical for high-titer viral replication. We find that HCMV infection substantially induces de novo pyrimidine biosynthetic flux. This activation is important for HCMV replication because inhibition of pyrimidine biosynthetic enzymes substantially decreases the production of infectious virus, which can be rescued through medium supplementation with pyrimidine biosynthetic intermediates. Metabolomic analysis revealed that pyrimidine biosynthetic inhibition considerably reduces the levels of various UDP-sugar metabolites in HCMVinfected, but not mock-infected, cells. Further, UDP-sugar biosynthesis, which provides the sugar substrates required for glycosylation reactions, was found to be induced during HCMV infection. Pyrimidine biosynthetic inhibition also attenuated the glycosylation of the envelope glycoprotein B (gB). Both glycosylation of gB and viral growth were restored by medium supplementation with either UDP-sugar metabolites or pyrimidine precursors. These results indicate that HCMV drives de novo-synthesized pyrimidines to UDP-sugar biosynthesis to support virion protein glycosylation. The importance of this link between pyrimidine biosynthesis and UDP-sugars appears to be partially shared among diverse virus families, because UDP-sugar metabolites rescued the growth attenuation associated with pyrimidine biosynthetic inhibition during influenza A and vesicular stomatitis virus infection, but not murine hepatitis virus infection. In total, our results indicate that viruses can specifically modulate pyrimidine metabolic flux to provide the glycosyl subunits required for protein glycosylation and production of high titers of infectious progeny.cytomegalovirus | pyrimidine | glycosylation | metabolism | UDP-sugar

Addiction to Coupling of the Warburg Effect with Glutamine Catabolism in Cancer Cells

“…Mass spectrometry was performed in negative mode with selected reaction monitoring (SRM)-specific scans as described in DeVito et al (2014) and Munger et al (2008). Further specifics regarding labeling, extraction, chromatography, and mass spectrometry data analysis can be found in the Supplemental Experimental Procedures.…”

Human Cytomegalovirus Can Procure Deoxyribonucleotides for Viral DNA Replication in the Absence of Retinoblastoma Protein Phosphorylation

“…7A and B). Others have shown that leflunomide inhibits infectious HCMV production, which can be partially reversed by adding a nucleoside precursor (51). Inhibition of de novo purine or pyrimidine synthesis did not appear to affect the accumulation of the mRNA encoding the HCMV DNA polymerase UL54 (Fig.…”

Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1

“…However, in the last several years, several groups have identified diverse molecules that inhibit pyrimidine biosynthesis and suppress viral growth (A3 and DD264), with cellular profiles suggesting mechanisms of antiviral resistance induction that extend beyond limitation of free nucleosides (Hoffmann et al, 2011; Lucas-Hourani et al, 2013). The antiviral activity of pyrimidine biosynthesis inhibitors such as A3 and DD264 has been demonstrated mainly against RNA viruses (e.g., influenza viruses A and B, Sendai virus, vesicular stomatitis virus, hepatitis C virus, West Nile virus and Dengue I virus), although some activity against DNA viruses (e.g., adenovirus 5, vaccinia, and a polyomavirus) has also been shown (DeVito et al, 2014; Hoffmann et al, 2011; Lucas-Hourani et al, 2013). Consistent with findings in the present study, earlier studies showed that the pyrimidine synthesis inhibitors leflunomide (used clinically as an immunosuppressive anti-rheumatic drug) and A3 have antiviral activity against HIV-1 (Hoffmann et al, 2011; Schlapfer et al, 2003).…”